Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group.

Wells RJ, Woods WG, Lampkin BC, Nesbit ME, Lee JW, Buckley JD, Versteeg C, Hammond GD.

J Clin Oncol. 1993 Mar;11(3):538-45.

PMID:
8445429
2.
3.

A systematic overview of chemotherapy effects in acute myeloid leukaemia.

Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):231-52. Review.

PMID:
11441935
4.

Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.

Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT.

J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. Review.

PMID:
11902303
5.

Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.

Büchner T, Hiddemann W, Löffler G, Gassmann W, Maschmeyer G, Heit W, Hossfeld D, Weh H, Ludwig WD, Thiel E, et al.

Semin Hematol. 1991 Jul;28(3 Suppl 4):76-9. Review. No abstract available.

PMID:
1780757
6.

Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Rashidi A, Walter RB, Tallman MS, Appelbaum FR, DiPersio JF.

Blood. 2016 Aug 11;128(6):763-73. doi: 10.1182/blood-2016-03-674127. Epub 2016 Jun 27. Review. No abstract available.

Supplemental Content

Support Center